Circular RNA circStag1 promotes bone regeneration by interacting with HuR

Gaoyang Chen1,2, Canling Long1,2, Shang Wang1,2, Zhenmin Wang1,2, Xin Chen1,2, Wanze Tang1,2, Xiaoxin He1,2, Zhiteng Bao1,2, Baoyu Tan1,2, Jin Zhao1,2, Yongheng Xie1,2, Zhizhong Li3, Dazhi Yang1,2, Guozhi Xiao4,5 and Songlin Peng1,2

Postmenopausal osteoporosis is a common bone metabolic disorder characterized by deterioration of the bone microarchitecture, leading to an increased risk of fractures. Recently, circular RNAs (circRNAs) have been demonstrated to play pivotal roles in regulating bone metabolism. However, the underlying functions of circRNAs in bone metabolism in postmenopausal osteoporosis remain obscure. Here, we report that circStag1 is a critical osteoporosis-related circRNA that shows significantly downregulated expression in osteoporotic bone marrow mesenchymal stem cells (BMSCs) and clinical bone tissue samples from patients with osteoporosis. Overexpression of circStag1 significantly promoted the osteogenic capability of BMSCs. Mechanistically, we found that circStag1 interacts with human antigen R (HuR), an RNA-binding protein, and promotes the translocation of HuR into the cytoplasm. A high cytoplasmic level of HuR led to the activation of the Wnt signaling pathway by stabilizing and enhancing low-density lipoprotein receptor-related protein 5/6 (Lrp5/6) and β-catenin expression, thereby stimulating the osteogenic differentiation of BMSCs. Furthermore, overexpression of circStag1 in vivo by circStag1-loaded adeno-associated virus (circStag1-AAV) promoted new bone formation, thereby preventing bone loss in ovariectomized rats. Collectively, we show that circStag1 plays a pivotal role in promoting the regeneration of bone tissue via HuR/Wnt signaling, which may provide new strategies to prevent bone metabolic disorders such as postmenopausal osteoporosis.

INTRODUCTION

Postmenopausal osteoporosis is the most common metabolic bone disorder, affecting nearly 200 million women worldwide1,2. Osteoporosis is characterized by altered bone mineralization and decreased bone mass, resulting in an increased probability of fracture3,4. Moreover, osteoporotic fractures cause major social and economic burdens due to limitations in patients’ mobility and daily activities as well as the costs associated with medical treatment, absence from work, and prolonged hospitalizations5–7. Estrogen decline is the leading cause of postmenopausal osteoporosis, which impairs bone homeostasis by promoting osteoclastic bone resorption and suppressing osteoblastic bone formation8,9. Currently, bisphosphonates are the top choice for the clinical treatment of osteoporosis9,10. Nonetheless, long-term use of bisphosphonates may lead to complications such as osteonecrosis11–13. A more complete understanding of the molecular pathogenesis of postmenopausal osteoporosis may lead to the discovery of new targets and biomarkers to aid in the prevention and treatment of this disorder.

Accumulating evidence has revealed that noncoding RNAs (ncRNAs) serve as critical regulators in the process of osteoporotic bone regeneration; thus, they are expected to become potential therapeutic targets for the prevention of osteoporosis14–18. Recently, circular RNAs (circRNAs) have attracted much attention for their vital roles in regulating the process of disease occurrence and development19–22. These molecules are more stable than linear RNAs due to their closed-loop structure protecting them from degradation by RNA exonuclease23,24. CircRNAs were initially thought to be byproducts of the splicing process without biological function19. In contrast, recent studies have found that circRNAs can regulate the translation of endogenous competitive miRNAs by sponging microRNAs (miRNAs)25–27. Interestingly, recent evidence has shown that circRNAs can fulfill vital roles in regulating the pathogenesis of diseases by interacting with RNA-binding proteins (RBPs)28,29. For instance, one recent study showed that circPDE4B prevents articular cartilage degeneration by interacting with RIC8A and MID1, indicating that circRNAs play critical roles in regulating chondrogenesis by interacting with RBPs29,30.

Moreover, emerging evidence has shown that some circRNAs are dysregulated in the peripheral blood of patients with osteoporosis25. Some of these circRNAs have been identified as modulators that regulate BMSC proliferation or differentiation by sponging miRNAs25. However, these prior studies have been limited to exploring the roles of osteoporosis-related circRNAs in sponging miRNAs. It remains unknown whether circRNAs can regulate bone metabolism through other mechanisms, such as by interacting with RBPs.

1Department of Spine Surgery and Institute for Orthopaedic Research, the Second Clinical Medical College of Jinan University (Shenzhen People’s Hospital), Shenzhen Key Laboratory of Musculoskeletal Tissue Reconstruction and Function Restoration, Shenzhen 518020, China; 2The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen 518055, China; 3The First Affiliated Hospital, Jinan University, Guangzhou 510630, China and 4School of Medicine, Southern University of Science and Technology, Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen Key Laboratory of Cell Microenvironment, Shenzhen 518055, China.

Correspondence: Dazhi Yang (yangdazhi1111@163.com) or Guozhi Xiao (xiaogzi@sustech.edu.cn) or Songlin Peng (dyffyy2@mail.sustech.edu.cn).

These authors contributed equally: Gaoyang Chen, Canling Long.

Received: 16 July 2021 Revised: 29 January 2022 Accepted: 28 February 2022

Published online: 31 March 2022

© The Author(s) 2022

Bone Research (2022) 10:32 ; https://doi.org/10.1038/s41413-022-00208-x

www.nature.com/boneres
Here, we show that circStag1, a circRNA with downregulated expression in the BMSCs of osteoporotic rats and bone tissues of patients with postmenopausal osteoporosis, can promote osteoporotic bone formation. We further demonstrated that circStag1 interacts with the HuR protein to promote the translocation of HuR into the cytoplasm. Cytoplasmic HuR then functions to stabilize and enhance low-density lipoprotein receptor-related protein 5/6 (Lrp5/6) and β-catenin expression, thereby activating the Wnt signaling pathway. Consequently, circStag1 was identified as a pivotal regulator of bone metabolism and may serve as a candidate therapeutic target to prevent postmenopausal osteoporosis.

RESULTS
CircStag1 expression is downregulated in osteoporosis
We isolated and cultured BMSCs from the bone marrow of ovariectomized (OVX) and sham-treated rats and found that the osteogenic capability of BMSCs from the OVX rats was significantly reduced (Fig. S1e, f). The expression of osteogenic marker genes showed a remarkable reduction in osteoporotic BMSCs (Fig. S1g, h). To identify potential osteoporosis-related circRNAs, we performed RNA sequencing to search for dysregulated circRNAs in osteoporotic BMSCs. This analysis revealed 54 circRNAs with upregulated and 65 with downregulated expression in the OVX group BMSCs compared to the sham group BMSCs (Fig. 1a; P < 0.05 and fold change ≥2). KEGG pathway enrichment analysis of their host genes revealed enrichment of several interesting pathways, including some that play critical roles in bone metabolism, such as the Wnt, Notch, and Hippo signaling pathways (Fig. 1b). Among these dysregulated circRNAs, 15 circRNAs with high homology (identity ≥95%) between humans and rats were identified (Fig. 1c, Table S1). The expression levels of these 15 circRNAs (10 upregulated and 5 downregulated) were further analyzed in the BMSCs of rats (OVX vs. sham, n = 10) and clinical bone samples (control vs. osteoporosis, n = 10) by qPCR, which showed that the expression of circFam13c, circCcb1, circTc2n, circArhgap26, and circCdk4 was significantly increased in osteoporotic BMSCs and clinical bone tissues (Fig. 1d, e), while a remarkable reduction was observed in the expression of circLcor1, circStag1, and circArh1 (Fig. 1f, g).

We then analyzed the dynamic expression of the dysregulated circRNAs in BMSCs during osteogenic induction and observed an increasing trend of circStag1 (circBase ID: hsa_circ_0003626) expression in osteogenically induced BMSCs (Fig. 1h), suggesting that it may be associated with the osteogenic capability of BMSCs. Next, we compared the expression of circStag1 with bone mineral density (T-score) and found a significant positive correlation (Fig. 2a, R = 0.80, P < 0.05). We then further analyzed the expression of osteogenic markers in clinical bone tissues and observed a remarkable reduction in the expression of osteogenic markers in the tissues of the patients with osteoporosis (Fig. 2b, c). Furthermore, Pearson correlation analysis revealed that the expression levels of osteogenic markers had positive correlations with circStag1 (Fig. 2d–f). Together, these results demonstrate that circStag1 is an osteoporosis-related circRNA that is positively correlated with bone mass and osteogenesis.

Overexpression of circStag1 stimulates the osteogenic capability of BMSCs
CircStag1 is an exon-derived circRNA generated from the stromal antigen 1 (Stag1) gene (Fig. 3a). Sanger sequencing was conducted with primers in exon 2 and exon 4 of circStag1, which demonstrated the presence of the backsplicing junction of circStag1 in BMSCs (Fig. 3b, Fig. S2a–c). We also constructed an overexpression plasmid (ov-circStag1) and small interfering RNA (si-circStag1) of circStag1 to test the effect of overexpressing or knocking down circStag1 on the expression of Stag1 mRNA. After circStag1 plasmid transfection, the expression of circStag1 was significantly increased (Fig. 3c), while no change was observed in the mRNA expression of Stag1 (Fig. 3d).

Conversely, the expression of circStag1 was markedly decreased after si-circStag1 transfection (Fig. 3e), while no change was observed in the expression of Stag1 mRNA (Fig. 3f). Furthermore, western blotting showed that overexpression of circStag1 does not affect the protein level of Stag1 (Fig. 3g), suggesting that circStag1 does not modulate the expression of Stag1.

Next, the localization of circStag1 was analyzed by fluorescence in situ hybridization (FISH), showing a significant distribution in the cytoplasm of BMSCs (Fig. 3h). The distribution of circStag1 in the cytoplasm was further validated by the subcellular fractionation method coupled with qPCR (Fig. 3i, j).

Next, we analyzed the effects of circStag1 overexpression on the osteogenic capability of BMSCs. Alizarin red S (ARS) and ALP staining showed that the osteogenic capability of BMSCs could be significantly enhanced by overexpressing circStag1 but remarkably attenuated by knocking down circStag1 (Fig. 3k, l). The expression of osteogenic marker genes was significantly increased by overexpressing circStag1, but decreased by knocking down circStag1 (Fig. 3m, n). Together, these results indicate a positive effect of circStag1 on regulating osteogenesis.

CircStag1 promotes the translational control of HuR protein into the cytoplasm
Previous studies have revealed the critical regulatory roles of exonic-derived circRNAs by sponging miRNAs, interacting with RBPs, or encoding peptides. A recent study found that circStag1 is a protein-binding RNA, which was further suggested by predictions from the RNA-binding protein database (RBPDB) and Circular RNA Interactome database. Interestingly, HuR was the only protein predicted to interact with circStag1 by both the RBPDB and Circular RNA Interactome databases (Fig. 4a). The predicted HuR-binding site of circStag1 is shown in Fig. 4b. Computational structural analysis indicated that four potential circStag1-interacting residues in HuR protein are crucial for its interaction with circStag1, including RNA recognition motif 1 (sites: K92, R131) (Fig. S3a) and RNA recognition motif 3 (sites: K285, K320) (Fig. S3b).

Next, RNA immunoprecipitation (RIP) experiments were applied to verify the interaction between circStag1 and HuR, showing that circStag1 was remarkably enriched in HuR immunoprecipitates compared to IgG immunoprecipitates (Fig. 4c). However, knocking out the effective HuR-binding sites of circStag1 significantly reduced this enrichment (Fig. 4d). A circStag1-specific biotin-labeled probe, which can identify the backsplice junction of circStag1, was synthesized to further confirm the interaction between circStag1 and HuR. A prominent enrichment of HuR was observed in the circStag1 probe group (Fig. 4e). There were no remarkable changes in the gene or total protein expression of HuR observed after circStag1 overexpression (Fig. 4f–h). However, subcellular fractionation assays showed that overexpressing circStag1 prominently upregulated the level of cytoplasmic HuR but downregulated its level in the nucleus (Fig. 4i, j). Furthermore, colocalization assays using FISH and immunofluorescence (IF) stains further verified that overexpression of circStag1 promoted HuR protein translocation from the nucleus to the cytoplasm (Fig. 4k). However, overexpression of a mutant form of circStag1 in which the HuR-binding sites (AU-rich element) were knocked out (circStag1HuR-KO) did not affect HuR protein localization (Fig. 4k). Altogether, these data demonstrate that circStag1 can interact with the HuR protein and promote its accumulation in the cytoplasm of BMSCs.

CircStag1 promotes the Wnt signaling pathway by altering the subcellular localization of the HuR protein in BMSCs
HuR, a nucleocytoplasmic shuttle protein, can regulate the stability of its target mRNAs. Recently, cytoplasmic HuR protein has been reported to activate the Wnt signaling pathway by stabilizing Lrp5/6 and β-catenin mRNAs, thereby increasing their protein expression. However, the roles of HuR in bone metabolism remain unclear. To further clarify whether HuR protein can activate
the Wnt signaling pathway in BMSCs, we conducted RIP assays to verify whether the Lrp5/6 and β-catenin mRNAs could bind to HuR. Indeed, we observed that the Lrp5/6 and β-catenin mRNAs were significantly enriched in HuR immunoprecipitates (Fig. S5a), while no significant enrichment of other Wnt signaling-related mRNAs was observed in the immunoprecipitates of HuR (Fig. S4). Furthermore, overexpressing HuR significantly increased Lrp5/6 and β-catenin expression (Fig. S5a–c), whereas their expression was decreased by knocking down HuR (Fig. S5d–f). In addition, Lrp5/6 and β-catenin were expressed at low levels in the clinical bone tissues of patients with osteoporosis, which showed a positive correlation with circStag1 (Fig. S5a–c).

These observations suggest that circStag1 may upregulate Wnt signaling by recruiting HuR protein to the cytoplasm. We carried out two experiments to test this hypothesis. First, we overexpressed WT or HuR-KO circStag1 and analyzed the Lrp5/6 and β-catenin expression levels. Consistent with our hypothesis, we observed that the Lrp5/6 and β-catenin levels were significantly overexpressed in the WT circStag1 group, while no impact was observed in the circStag1 HuR-KO group (Fig. 5b,c).

Next, we overexpressed circStag1 with or without HuR siRNA. Again, we observed significantly increased mRNA and protein levels of Lrp5/6 and β-catenin in the circStag1 overexpression sample, but this effect was abrogated by cotransfection of HuR siRNA (Fig. 5d–f).

CircStag1 promotes bone regeneration by interacting with the HuR protein. Given that circStag1 could promote the translocation of HuR to the cytoplasm of BMSCs, thereby upregulating the Wnt signaling...
pathway, we sought to test whether circStag1 promotes osteogenesis of BMSCs via the interaction with HuR protein. To do so, we again overexpressed circStag1 and found that this overexpression significantly stimulated the expression of osteogenic marker genes (Fig. 5g–i). However, these effects were prevented by cotransfection with si-HuR. Furthermore, the ARS and ALP staining results showed that overexpressing circStag1 significantly stimulated the osteogenic differentiation of BMSCs (Fig. 5j, k), which was also prevented by cotransfecting si-HuR. Together, these results support the model in which circStag1 promotes the osteogenesis of BMSCs by recruiting HuR protein into the cytoplasm, leading to the activation of the Wnt signaling pathway.

The bone formation capacity of the OVX rats is promoted by overexpression of circStag1. Given that circStag1 is a promoter of osteogenesis, the effect of circStag1 on bone regeneration was further explored in vivo with circStag1-loaded AAV (circStag1-AAV) in rats (Fig. 7a). First, the effect of circStag1-AAV on BMSCs was analyzed in vitro, which demonstrated its ability to promote osteogenesis (Fig. 7a). Next, four groups of rats were assessed in this study: the sham control group, OVX group, control AAV-injected OVX group, and circStag1-AAV-injected OVX group. After four injections over 4 weeks, the rats were euthanized, and the bone tissues and primary organs were collected. The expression of circStag1 in each organ was then detected by qPCR. CircStag1 was expressed at significantly lower levels in the bone tissue of the OVX rats than in the sham control rats, while circStag1-AAV treatment significantly increased the level of circStag1 in osteoporotic bone tissues (Fig. 7c). Additionally, a slight increase in circStag1 was observed in the liver and spleen of the OVX rats injected with circStag1-AAV (Fig. 7d). However, no significant changes in tissue weight or histological features of primary organs were observed in the OVX rats injected with circStag1-AAV compared to those injected with saline or AAV control (Fig. 5a, b).

Next, micro-CT and bone histomorphometry analyses were performed to test the effect of circStag1 on bone regeneration. The micro-CT results showed that circStag1-AAV treatment could markedly prevent bone loss caused by ovariectomy (Fig. 6a). The static bone histomorphometric indices, including bone mineral density, bone volume, trabecular thickness and number, and the number of osteoblasts, trabecular bone area, and cortical thickness markedly decreased after ovariectomy, but these effects were also partially rescued by circStag1-AAV injection (Fig. 6b, c). Analysis of undecalcified bone histology showed a significant reduction in new bone formation in the OVX rats, but this effect could be partially prevented by circStag1-AAV injection (Fig. 6d, e). Furthermore, a significant decline in the mineral apposition and bone formation rate in the OVX rats was observed but could largely be prevented by treatment with circStag1-AAV (Fig. 6f, g). The mechanical strength indices, including bone stiffness, and max strength, were also improved after circStag1-AAV injection (Fig. 6h, i).

TRAP staining was also performed to show the effect of circStag1 on bone resorption, with a result showing that circStag1-AAV injection could significantly reduce the number of osteoclasts caused by ovariectomy (Fig. 5a). The serum level of the bone resorption marker CTX-I was also reduced after circStag1-AAV injection (Fig. 5b). These results suggest that AAV injection could significantly restrain bone resorption in the OVX rats by reducing the number of osteoclasts.

At the molecular level, we observed that Lrp5/6 and β-catenin were significantly expressed at low levels in the bone tissue of the OVX rats, but this effect was largely rescued by circStag1 treatment (Fig. 7f). The Lrp5/6 and β-catenin protein levels were in accordance with the qPCR results (Fig. 7d). Likewise, osteogenic markers were also substantially expressed at low levels in the bone tissue of the OVX rats, an effect that was largely prevented by circStag1-AAV but not control-AAV treatment (Fig. 7f). Their protein levels were also consistent with the qPCR results (Fig. 7g–j). Taken together, the above results demonstrate that circStag1-AAV treatment could prevent bone loss in OVX rats.
Fig. 3  CircStag1 promotes osteogenesis of BMSCs. a CircStag1 is generated from exons 2–4 of the Stag1 gene. b The presence of the backsplicing junction of circStag1 was validated by Sanger sequencing. c CircStag1 plasmids significantly increased the expression of circStag1 (n = 3, ***P < 0.001). d CircStag1 plasmid transfection had no significant impact on the mRNA level of Stag1 (n = 3). e Si-circStag1-1 resulted in the strongest knockdown of circStag1 (n = 3, *P < 0.05, **P < 0.01, ***P < 0.001). f CircStag1 siRNAs had no significant impact on Stag1 mRNA expression (n = 3). g Western blotting analysis showed that no significant change in Stag1 protein levels was observed after overexpressing circStag1 (n = 3). h RNA FISH analysis of the subcellular localization of circStag1 in BMSCs. Red fluorescence represents circStag1, and blue fluorescence represents nuclei (n = 3). i, j Subcellular fractionation was performed, and the relative expression of cytoplasmic and nuclear circStag1 was detected (n = 3, ***P < 0.001). k, l Alizarin red and ALP staining showed that overexpressing circStag1 significantly promoted, while siRNA knockdown of circStag1 significantly decreased, the osteogenic differentiation of BMSCs (n = 3, ***P < 0.001). m, n Overexpressing circStag1 significantly increased the mRNA and protein levels of osteogenic marker genes (n = 3, ***P < 0.001). o, p Knocking down circStag1 significantly decreased the mRNA and protein levels of osteogenic marker genes (n = 3, *P < 0.05, **P < 0.01, ***P < 0.001)
CircStag1 promotes HuR translocation into the cytoplasm. **a** HuR is the only protein predicted to interact with circStag1 by both the RBPDB and circRNA interaction databases. **b** Three-dimensional structure of circStag1 highlighting the HuR-binding sites. **c** RIP assays showed that circStag1 was significantly enriched in the immunoprecipitates of HuR compared with those of IgG (n = 3, ***P < 0.001). **d** Knocking out the effective HuR-binding sites of circStag1 significantly reduced its enrichment in the immunoprecipitates of HuR compared to the wild-type circStag1 (n = 3, ns no significance, ***P < 0.001). **e** RNA pulldown showed that HuR was pulled down with a biotin-labeled circStag1 probe (n = 3). **f** Overexpressing circStag1 had no significant impact on HuR mRNA expression (n = 3). **g, h** Overexpressing circStag1 had no significant impact on the total HuR protein level (n = 3). **i, j** The level of cytoplasmic HuR protein significantly increased, while the level of nuclear HuR protein significantly decreased, after overexpressing circStag1 (n = 3, ***P < 0.001). **k** Fluorescence localization analysis of circStag1 and HuR showed that overexpressing circStag1 could significantly promote the translocation of HuR into the cytoplasm, while no change in HuR localization was found after circStag1HuR-KO overexpression compared to that of the control group (n = 3).
Fig. 5 CircStag1 activates the Wnt signaling pathway by interacting with HuR. a RIP assays showed that Lrp5/6 and β-catenin mRNAs were significantly enriched in the immunoprecipitates of HuR compared with those of IgG (n = 3, ***P < 0.001). b, c The mRNA and protein levels of Lrp5/6 and β-catenin increased dramatically by overexpression of WT circStag1 but not by HuR-KO circStag1 (n = 3, ns no significance, ***P < 0.001). d-f The mRNA and protein levels of Lrp5/6 and β-catenin increased dramatically with circStag1 overexpression, which could be largely prevented by cotransfection with si-HuR (n = 3, ***P < 0.001). g–i The mRNA and protein levels of Alp, Opn, and Ocn significantly increased with circStag1 overexpression, which could be largely prevented by cotransfection with si-HuR (n = 3, ***P < 0.001). j, k Alizarin red and ALP staining showed that overexpressing circStag1 substantially promoted the osteogenic differentiation of BMSCs, but the effect was largely prevented by cotransfection with si-HuR (n = 3, ***P < 0.001)
Fig. 6 Overexpressing circStag1 can promote bone formation in OVX rats. a The bone microstructure analyzed by micro-CT scanning showed a remarkable reduction in bone mass in the OVX rats compared to the sham-treated rats, and this effect could be significantly reversed by circStag1-AAV (but not control-AAV) injection (n = 6). b The static bone histomorphometric indices (BMD, Tb.Th, BV/TV, and Tb.N) were significantly lower in the OVX rats than the sham-treated rats, and these parameters were significantly improved by injecting circStag1-AAV but not control-AAV (n = 6, ***P < 0.001). c H&E staining showed that the trabecular bone area, cortical thickness, and density of osteoblasts in the OVX rats were reduced compared to those in the sham group; however, these effects were remarkably improved by injecting circStag1-AAV (n = 6). d, e The double calcein labeling width in cortical and trabecular bone was significantly reduced in the OVX rats but was largely improved by injecting circStag1-AAV (n = 6). f, g The dynamic bone histomorphometric indices, including MAR and BFR/BS, were remarkably lower in the OVX rats than in the sham-treated rats but were significantly improved by circStag1-AAV injection (n = 6, ***P < 0.001). h The displacement-load curves of the 3-point bending test (n = 6). i A significant reduction in the mechanical strength indices (maximum force, stiffness, and maximum strength) was observed in the OVX group compared to the sham group but was significantly improved by treatment with circStag1-AAV (n = 6, *P < 0.05, **P < 0.01, ***P < 0.001).
Fig. 7 Overexpressing circStag1 promotes the expression of Lrp5/6, β-catenin, and osteogenic marker genes in bone samples of OVX rats. a–e qPCR, WB, and IF staining of bone tissues showed a significant reduction in Lrp5/6 and β-catenin in the OVX rats. However, their expression levels could be largely rescued by circStag1-AAV injection but not control-AAV (n = 6, ***P < 0.001). f–j qPCR, WB, and IF staining of bone tissue samples showed a significant reduction in osteogenic marker genes (Opn, Ocn, and Alp) in the OVX rats. However, their expression levels could be largely rescued by treatment with circStag1-AAV but not control-AAV (n = 6, ***P < 0.001).
DISCUSSION
CircRNAs have attracted increased attention as they have been observed to be critical regulators of disease progression. Recent studies have found that some circRNAs are dysregulated in the peripheral blood of patients with osteoporosis, and some of these circRNAs act as regulators that control bone formation by sponging mRNAs. Emerging evidence suggests that RNA-binding proteins play pivotal roles in the regulation of circRNAs. For instance, circBACH1 has been found to regulate p27 expression by interacting with HuR, thereby promoting hepatocellular carcinoma growth. Shen et al. demonstrated that circPD443 can function as a scaffold for MID1 and RIC8A, thereby preventing articular cartilage degeneration in osteoarthritis. However, it remains unknown whether circRNAs can regulate bone metabolism by interacting with RBPs, prompting us to analyze the functions of circRNAs in osteoporotic bone regeneration in the current study.

In this study, circStag1 expression was identified to be significantly downregulated in BMSCs of osteoporotic rats and bone tissue samples of patients with osteoporosis, suggesting its close relationship with osteoporosis. Moreover, in vitro assays further revealed that circStag1 overexpression significantly enhanced the osteogenic capability of BMSCs. Huang et al. showed that circStag1 is a protein-binding circRNA that can capture ALKBH5 and decrease its accumulation in the nucleus, leading to the attenuation of depressive-like behaviors. In our present work, we first predicted that circStag1 could interact with HuR. Previous studies have shown that HuR, a type of RBP, can recognize the AU-rich element (ARE) on RNAs. Recent evidence suggests that some circRNAs with ARE sites can interact with HuR and alter its subcellular localization. Evidence suggests that some circRNAs with ARE sites can interact with HuR and alter its subcellular localization. For instance, circAG02 could interact with HuR by recognizing its RNA recognition motif, which then led to translocation of HuR into the cytoplasm. Similarly, circDCU1-LF was found to interact with HuR and promote its translocation into the cytoplasm, resulting in the suppression of glycolysis and metastasis in lung adenocarcinoma. In this study, we identified HuR as a top candidate circStag1 binder using computational structural prediction, which was then validated experimentally by RIP and pulldown assays. Consistently, in vitro colocalization assays showed that circStag1 promoted the translocation of HuR into the cytoplasm in BMSCs.

Since HuR can recognize and stabilize various RNAs, thereby regulating processes including the cell cycle, proliferation, differentiation, or apoptosis via AREs, we further explored mRNAs that could potentially interact with HuR in BMSCs. Marta et al. analyzed HuR using RNA-protein immunoprecipitation combined with mRNA microarray technology and found that HuR-binding mRNAs exhibit enrichment of the Wnt signaling pathway. The canonical Wnt signaling pathway mediated by β-catenin has been implicated in bone homeostasis. By recognizing frizzled (Fz) family proteins and Lrp5/6, Wnt members can suppress the activity of glycogen synthase kinase 3 beta (Gsk-3β), thereby inducing β-catenin translocation into the nucleus. Nuclear β-catenin can promote the expression of osteogenic markers by interacting with the CREB-binding protein and T-cell factor/lymphocyte enhancer factor 1 complex. Moreover, several studies have shown that cytoplasmic HuR can stabilize Lrp5/6 and β-catenin mRNAs, thereby increasing their protein expression and enhancing Wnt signaling activity. Consistently, in the present study, we found that circStag1-induced cytoplasmic accumulation of HuR could activate the Wnt signaling pathway by stabilizing Lrp5/6 and β-catenin mRNAs, thereby promoting the osteogenesis of BMSCs.

Given our observation that circStag1 acts as a pivotal regulator in controlling the osteogenesis of BMSCs, in vivo analyses were further performed to examine the effects of circStag1 on promoting osteoporotic bone regeneration. Previously, it was a challenge to determine the in vivo roles of osteogenesis-related ncRNAs owing to the lack of stable and efficient carriers. Vectors with a high transfection ability and good biocompatibility are the keys to the therapeutic efficacy of gene therapy. Adeno-associated virus (AAV) has been suggested to be an ideal vehicle for the delivery of circRNAs. Recently, many studies have demonstrated that AAVs can be used as a gene therapy vector for BMSCs. Based on these positive results, we constructed circStag1-AAV to explore the in vivo effects of circStag1 on bone formation. Importantly, we observed that circStag1-AAV treatment significantly prevented bone loss in the OVX rats. Functionally, mechanical strength was also improved by circStag1-AAV treatment. In addition, the expression levels of Lrp5/6, β-catenin, and osteogenic marker genes were all significantly increased in the bone tissue of the circStag1-AAV-treated OVX rats. Taken together, these findings demonstrate that circStag1 is a positive regulator of osteogenic bone regeneration. Moreover, overexpression of circStag1 in vivo can promote bone formation, indicating that circStag1 is a potential therapeutic target for postmenopausal osteoporosis.

In this study, we explored the mechanism of circStag1 in regulating osteoporotic bone regeneration and found it to be a key regulator of bone regeneration as well as a potential therapeutic target for osteoporosis. Nonetheless, these findings must be interpreted with caution, and potential limitations should be considered. First, the present study focused on understanding the regulatory mechanism of circStag1 in bone regeneration, but its role in osteoclast-induced bone resorption needs to be further explored. Second, the delivery vehicle used to validate the in vivo effects of circStag1 on bone regeneration is not ideal for clinical use. Although we found that our circStag1-loaded AAV had no significant side effects on the primary organs, the AAV vectors used in this study cannot target bone. Bone targeting vehicles for circRNAs still need to be explored to increase specificity and efficacy and to avoid unwanted side effects. Our future research will focus on addressing these concerns.

CONCLUSION
In conclusion, we provide evidence that circStag1 promotes osteoporotic bone regeneration. Mechanistically, circStag1 interacts with HuR protein and transports nuclear HuR protein into the cytoplasm, thereby promoting the expression of osteogenic genes by enhancing the activity of the Wnt signaling pathway. Our study provides new insights into the regulation of bone metabolic disorders via the interaction of a circRNA with an RBP, which sets a theoretical foundation for the application of circStag1 in preventing postmenopausal osteoporosis.

MATERIALS AND METHODS
BMSC isolation and culture
All animal experiments were approved by the Animal Ethics Committee of Jinan University. Sprague-Dawley rats (female, eight weeks old) were obtained from the Medical Experimental Animal Center of Guangdong Province, randomly split into two groups, and then underwent sham operation (n = 10) and bilateral ovariectomy (n = 10) (Fig. S1a, b). Each rat received an intramuscular penicillin injection (80 000 units/rat) for three days after the operation. All rats were euthanized two months after the operation. The bone marrow of each rat was collected from bilateral femurs in an aseptic environment and separated by density gradient centrifugation at a speed of 1 200 r min⁻¹. Then, BMSCs were cultured in alpha-modified Eagle’s medium (Gibco, Thermo Scientific, USA) with 10% fetal bovine serum (FBS, Gibco, Thermo Scientific, USA) and 1% penicillin and streptomycin (Gibco, USA) at 37 °C with 5% CO₂ and 95% humidity (Fig. S1c). The culture medium was replaced every three days. The expression of specific cell surface markers of BMSCs was verified (Fig. S1d).
In addition, human BMSCs were purchased from the American Type Culture Collection (Manassas, USA) and cultured in alpha-modified Eagle’s medium (10% FBS and 1% penicillin and streptomycin) at 37°C with 5% CO₂ and 95% humidity.

Human samples
A total of 20 postmenopausal women who underwent spinal fusion surgery at Shenzhen People’s Hospital were included in this study (Table S2). Their bone mineral density was measured and is presented as a T-score. Participants with T scores ≤ −2.5 SD were assigned to the osteoporosis group (n = 10), while those with T scores ≥ −1.0 SD formed the control group (n = 10)13. Participants with other metabolic diseases, such as osteonecrosis, rheumatoid arthritis, and diabetes, were excluded from the study. Bone tissue (100 mg) was obtained from each patient during the operation and then placed in a liquid nitrogen jar for preservation. The sample collection procedures were approved by the research ethics committee of Shenzhen People’s Hospital. Written informed consent was obtained from each participant.

RNA sequencing
The TRizol method (Invitrogen, USA) was performed to extract the total RNA of BMSCs from the OVX and sham-treated rats (n = 3). Then, the circRNA expression profile in BMSCs was detected by RNA sequencing (RiboBio Co., Ltd., Guangzhou, China)22. In brief, rRNA and linear RNA were first removed by using the RiboBio RNA removal kit and RNase R. Then, circRNA was reverse transcribed to cDNA. High-throughput sequencing was performed to generate the raw data by using an Illumina HiSeq 3000 system. Then, CIRI2 and CIRCexplorer2 software were used to identify circRNAs. Subsequently, sequence prediction, expression value calculation, and expression difference analysis were performed for the identified circRNAs. Any circRNA with P < 0.05 and fold change ≥2 was regarded as a differentially expressed circRNA20. The expression trends of these dysregulated circRNAs are shown by heatmaps and volcano plots. Pathway enrichment among the host genes of the dysregulated circRNAs was identified using KEGG pathway enrichment analysis.

Quantitative real-time PCR
AG RNAex Pro Reagent (AG21102, Accurate Biotechnology, Hunan, China) was used to collect total RNA from bone samples or BMSCs following the standard protocol. Then, total RNAs were reverse transcribed to cDNA using the PrimeScript reagent kit (TaKaRa, Tokyo, Japan), Salmon DNA Mayonnaise Co., Ltd. (Shanghai, China) designed and synthesized the primers for quantitative real-time PCR (qPCR) (Table S3). Then, qPCR was performed using TB Green premix (TaKaRa, Tokyo, Japan). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control for circRNAs and mRNAs, while U6 was used as the internal control for miRNAs.

CircStag1-HuR modeling structure
The potential interacting proteins of circStag1 were predicted using RBpdb (http://rbpdb.cbcr.utoronto.ca/) and the Circular RNA Intaractome (https://circinteractome.nia.nih.gov/) databases. For circRNA structure modeling, we used RNAComposer (http://rnacomposer.cs.put.poznan.pl/) to predict the three-dimensional structure of circStag1, running it in interactive mode with the circStag1 sequence as input53,54. For this analysis, we chose the select secondary structure prediction method, and we chose the ContextFold method from the drop-down list55. For the HuR protein structure, we separately chose the HuR-RRM1-2 structure (Protein Data Bank code 4EGL) and HuR-RRM3 structure (Protein Data Bank code 6GC5) as the docking template36. The HADDOCK2.4 webserver (https://bianca.science.uu.nl/haddock2.4) was used to separately dock HuR-RRM1-2 and HuR-RRM3 with circStag and predict the biomolecular interactions between circStag1 and the RNA recognition motifs of the HuR protein57. The input data consisted of the circStag1 and HuR models described above; ambiguous restraints for the complex docking interaction interface and the unambiguous distance restraints were used.

Cell transfection
Small interfering RNAs against circStag1 and HuR (Table S4), control siRNAs, overexpression plasmids for HuR (ov-HuR) and circStag1 (ov-circStag1), and mutant forms of circStag1 were synthesized by Hanbio Co., Ltd. (Shanghai, China). BMSCs were seeded into plates for 24 h and then transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the standard protocol.

Western blot
Total protein was extracted using the RiboBio Protein Extraction Kit (Signalway Antibody LLC, Maryland, USA) following the manufacturer’s instructions. Proteins were separated on SDS-PAGE gels and then transferred to PVDF membranes (Millipore, Massachusetts, USA), which were blocked with TBST containing 5% skim milk and incubated with anti-Stag1 (Proteintech, China; 14015-1-AP; 1:1 000), anti-β-catenin (Santa Cruz Biotechnology, USA; sc-7693; 1:1 000), anti-Lrp5 (Thermo, USA; 36-5400; 1:1 000), anti-Lrp6 (Thermo, USA; sc-101047; 1:1 000), anti-Hur (Abcam, UK, ab200342; 1:1 000), anti-β-tubulin (Cell Signaling Technology, USA; 2146; 1:1 000), anti-Alp (Santa Cruz Biotechnology, USA; sc-36525; 1:1 000), anti-Opn (Santa Cruz Biotechnology, USA; sc-2174; 1:1 000), anti-Ocn (Santa Cruz Biotechnology, USA; sc-9086; 7:1 1000), anti-Lamin B1 (Abcam, UK; ab16048; 1:5 000), and anti-GAPDH (Abcam, UK; ab4885; 1:5 000) at 4°C overnight. Finally, the membranes were hybridized with secondary antibodies at room temperature for 1 h and visualized using Rapid™ ECL Reagent (Millipore, USA).

Immunofluorescence
Samples were fixed in 4% paraformaldehyde, permeabilized with 0.25% Triton X-100 in PBS for 15 min, blocked with 10% goat serum for 1 h at 37°C and incubated with anti-Lrp5, anti-Lrp6, anti-β-catenin, anti-Hur, anti-Alp, anti-Opn, and anti-Ocn antibodies overnight at 4°C. Next, the samples were incubated with the secondary antibody in a 1:200 dilution ratio in PBS for 30 min at 37°C in the dark, followed by nuclear staining with DAPI (Abcam, Cambridge, UK). Fluorescence images were acquired using a Leica DMi8 microscope (Carl Zeiss Microlmaging GHGH, Jena, Germany).

RNA fluorescence in situ hybridization
Cy3-labeled probes for the backsplicing junction of circStag1 (Table S5), U6, and 18S were synthesized by RiboBio (RiboBio Biotechnology, Guangzhou, China). The hybridization was performed in a humidification chamber at 37°C for 16 h. The circStag1 signals were detected using a Fluorescent in Situ Hybridization Kit (RiboBio, Guangzhou, China) following the manufacturer’s instructions41. Fluorescence images were collected using a Leica DMi8 microscope.

Biotin-labeled RNA pulldown
CircStag1 probes with biotin labels and control probes were synthesized by RiboBio Biotechnology (Table S5). Biotin-labeled RNA pulldown was performed using the Pierce™ Magnetic RNA-Protein Pull-Down Kit (Thermo, USA) following the manufacturer’s instructions. Briefly, the probes (50 pmol·L⁻¹) were incubated with streptavidin-coated magnetic beads for 30 min at room temperature. The cells were lysed with Thermo Scientific Pierce IP Lysis Buffer (Thermo, USA), incubated with the probe-bound magnetic beads and rotated for 1 h at 4°C. Then, the probe-bead-protein complex was washed and eluted.
complex was washed three times with washing buffer. The proteins in the complex were extracted and detected by western blotting.

RNA immunoprecipitation
A Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) was used to validate the interaction between circStag1 and HuR protein. In brief, magnetic beads were coated with 5 μg of antibodies, including anti-HuR (Abcam, UK) and anti-immunoglobulin G (IgG) (Millipore, USA), for 30 min at room temperature. The cell lysate from 2 x 10^6 cells was incubated with antibody-coated magnetic beads overnight at 4 °C. Then, the bead-protein-RNA complexes were washed with RIP washing buffer six times, incubated with proteinase K digestion buffer, and rotated for 30 min at 55 °C. Finally, RNA was extracted and reverse transcribed to cDNA, and the level of circStag1 was detected via qPCR and normalized to the input.

Osteogenic induction
BMSCs were seeded into 6- or 48-well plates and cultured in alpha-modified Eagle’s medium. After cell attachment, the culture medium was changed to osteogenic medium supplemented with 10% FBS, 50 μg·mL^-1 ascorbate, 10 μmol·L^-1 β-glycerophosphate, 0.1 μmol·L^-1 dexamethasone, and 10 μmol·L^-1 glutamine (Cyagen Biosciences, Guangzhou, China). The osteogenic induction medium was replaced every 2 days.

Alizarin red and ALP staining
The osteogenic differentiation capability of BMSCs was validated by Alizarin red S staining (ARS) and ALP staining at Day 7 after transfection. In brief, BMSCs were seeded in 48-well plates and cultured in osteogenic medium. After 7 days of induction, the cells were fixed with 4% paraformaldehyde for 10 min and stained with ARS staining solution (Cyagen, China) at pH 8.3 for 30 min. After two washes, the staining area was photographed by light microscopy. Additionally, a BCIP/NBT ALP Color Development Kit (Beyotime, China) was applied to detect the expression of ALP. The stained cells were also photographed by light microscopy.

CircStag1-AAV construction and injection
Adeno-associated virus (AAV) was used as a vehicle for circStag1 to validate its in vivo function. In brief, recombinant AAV-9 containing the circStag1 sequence (circStag1-AAV) was synthesized by Hanbio Co., Ltd. (Shanghai, China) and diluted in PBS to 1 x 10^10 virus particles per mL. Female Sprague-Dawley rats (eight weeks old) were purchased and assigned to the sham control group, O VX group, control AAV-injected O VX group, and circStag1-AAV-injected O VX group (n = 6). Three days after ovarioectomy, circStag1-AAV (or the same dose of normal saline or control AAV) was injected into the tail vein of the rats at a dose of 2 x 10^11 v y r a t per week for 4 weeks. Calcein green (10 mg·kg^-1 body weight) was injected intraperitoneally at Days 9 and 2 before euthanasia. One week after the last AAV injection, all rats were euthanized, and the samples of primary organs of each rat were collected to test the impact of circStag1-AAV on primary organs. The femurs and tibias were collected for detecting bone formation and mechanical strength analysis.

Micro-CT
The right femurs (fixed in 4% paraformaldehyde) were scanned by using a micro-CT system (SkyScan 1276, Bruker, Belgium). The parameters used in micro-CT scanning were as follows: current of 100 μA, voltage of 80 kVp, pixel size of 20 μm, and exposure time of 926 ms. After scanning, NRecon software was used to construct 3D images of the distal metaphysis. Parameters of bone static histomorphometry, including BMD, Tb.N, BV/TV, and Tb.Th, were analyzed.

Bone histomorphometry
The trabecular bone of the distal right femur was dehydrated with a 20% sucrose solution, and frontal sections (10 μm thickness) were made using a Leica SM2500E microtome (Leica Microsystems). Then, fluorescence microscopy was used to collect fluorescent images of calcine green. Then, the dynamic bone histomorphometric parameters, including MAR and BFR/BS, were calculated using ImageJ (NIH, USA).

Bone mechanical properties
Three-point bending assays were conducted to examine the mechanical properties of rat tibias using a strength testing device (AG-IS, Shimadzu, Japan). The fresh tibias were wrapped in normal saline-soaked gauze and then centered longitudinally with the anterior surface on the two lower support points (20 mm distance). A third rounded bar was placed at the medial surface of the diaphysis with a 10 N pre-load strength. Then, a constant displacement rate of 0.5 mm·s^-1 was applied until fracture occurred during three-point bending (Trapezium X, Shimadzu, Japan). The mechanical data were generated and analyzed to determine the maximum load, stiffness, and maximum strength.

Statistical analysis
The expression data were presented as the mean ± standard deviation (x ± s). GraphPad Prism 7.5 was used to analyze the data. The difference among the three or more groups was considered statistically significant. The differentially expressed circRNAs were those with P < 0.05 and fold change ≥2. The Pearson correlation coefficient was used to analyze the correlation between circStag1 and its downstream genes.

ACKNOWLEDGEMENTS
The Shenzhen Municipal Science and Technology Innovation Committee Project (JCYJ20190806160407178, JCYJ20180305164544288, JSGG20180504170427135, SGLH2018062514600256, JCYJ201803051645459637) and the Shenzhen Key Laboratory of Musculoskeletal Tissue Reconstruction and Function Restoration (ZDSYS20200811143752005) supported this work.

AUTHOR CONTRIBUTIONS
Study design: G.C., C.L., G.X. and S.P. Study conduction and data collection and analysis: G.C., C.L., Z.W., S.W., X.C., W.T. and X.H. Data interpretation: G.C., C.L., Z.W., S.W., X.C., W.T. and X.H. All authors have read and approved the paper.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41413-022-00208-x.

Competing interests: The authors declare no competing interests.

REFERENCES
1. Black, D. M. & Rosen, C. J. Clinical practice. postmenopausal osteoporosis. N. Engl. J. Med. 374, 254–262 (2016).
2. Yardimci, A., Ozgude, M. R. & Kelestimur, H. Agomelatine, A potential multi-target treatment alternative for insomnia, depression, and osteoporosis in postmenopausal women: a hypothetical model. Front. Psychiatry 12, 654611 (2021).
3. Armas, L. A. & Recker, R. R. Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol. Metab. Clin. North Am. 41, 475–486 (2012).
4. Brandall, C. J. et al. Serial bone density measurement and incident fracture risk discrimination in postmenopausal women. JAMA Intern. Med. 180, 1232–1240 (2020).
5. Barron, R. L., Oster, G., Grauer, A., Cittenden, D. B. & Weycker, D. Determinants of imminent fracture risk in postmenopausal women with osteoporosis. Osteoporos. Int. 31, 2103–2111 (2020).
6. Black, D. M. & Rosen, C. J. Clinical practice. Postmenopausal osteoporosis. *N. Engl. J. Med.* **374**, 254–362 (2016).
7. Snyder, S. Biphosphonates for osteopenia in postmenopausal women. *JAMA* **323**, 1096 (2020).
8. Ensrud, K. E. Biphosphonates for postmenopausal osteoporosis. *JAMA* **325**, 96 (2021).
9. Otto, S. et al. A drug holiday reduces the frequency and severity of medication-related osteonecrosis of the jaw in a minipig model. *J. Bone Min. Res.** **35**, 2179–2192 (2020).
10. Wan, J. T., Shealey, D. M., Sonneman, M. J. & Lee, J. S. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. *Bone Res.* **8**, 14 (2020).
11. Krzeszinski, J. Y. et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. *Nature* **512**, 431–435 (2014).
12. Li, M. et al. A novel IncRNA LNC_000052 leads to the dysfunction of osteoblastic BMSCs via the miR-96-5p-PKCI31 axis. *Cell Death Dis.* **11**, 795 (2020).
13. Liu, M. et al. Circulating microRNA-19b identified from osteoporotic vertebral compression fracture patients increases bone formation. *J. Bone Min. Res.** **35**, 306–316 (2020).
14. Xu, R. et al. Identification of the canonical and noncanonical role of miR-143/145 in estrogen-deficient bone loss. *Theranostics* **11**, S491–S510 (2021).
15. Baumann, K. CircRNAs in IFSipan. *Nat. Rev. Mol. Cell Biol.* **21**, 420 (2020).
16. Zhao, Q. et al. Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing miROS output. *Cell** **183**, 76–93.e22 (2020).
17. Kristensen, L. S. et al. The biogenesis, biology and characterization of circular RNAs. *Nat. Rev. Genet.* **18**, 331–357 (2017).
18. Gu, Y. et al. CircRNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling. *Mol. Cancer** **20**, 132 (2021).
19. Hansen, T. B. et al. Natural RNA circles function as efficient microRNA sponges. *Nature* **495**, 384–388 (2013).
20. Chen, G. et al. Circular RNA CDR1as promotes adipogenesis and suppresses osteogenic differentiation of BMSCs in steroid-induced osteonecrosis of the femoral head. *Bone** **133**, 115268 (2020).
21. Zeng, Z. et al. Circular RNA CircMAPPK5 acts as a MicroRNA-22-3p sponge to promote resolution of intimal hyperplasia via TET2-mediated smooth muscle cell differentiation. *Circulation* **143**, 354–371 (2021).
22. Guarenio, J. et al. Intragenic antagonist roles of protein and circular RNA in tumorigenesis. *Cell Res.* **29**, 628–640 (2019).
23. Huang, A., Zheng, H., Wu, Z., Chen, M. & Huang, Y. Circular RNA-protein interactions: functions, mechanisms, and identifications. *Theranostics** **10**, 3503–3518 (2020).
24. Shen, S. et al. circPDE4B prevents articular cartilage degeneration and promotes cartilage repair by acting as a scaffold for RIC8A and MID1. *Ann. Rheum. Dis.* **79**, 1209–1219 (2020).
25. Chen, G. et al. Promising diagnostic and therapeutic circRNAs for skeletal and chondral disorders. *Int. J. Biol. Sci.* **17**, 1428–1439 (2021).
26. Shao, T., Pan, Y. H. & Xiong, X. D. Circular RNA: an important player with multiple functions in epithelial ovarian cancer. *Cell Biol. Int.* **152**, 1477–1491 (2017).
27. Chiu, C. et al. Long noncoding RNA IncARS1 promotes epithelial ovarian cancer cell proliferation and invasion by association with HUR and miR-200 family. *Am. J. Cancer Res.* **8**, 981–992 (2018).
28. Palomo-Irigoyen, M. et al. HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. *J. Clin. Invest.* **130**, 3848–3864 (2020).
29. Yang, Q., Li, F., He, A.-T. & Yang, B. B. Circular RNAs: expression, localization, and therapeutic potentials. *Mol. Ther.* **29**, 1683–1702 (2021).
30. Yu, L. & Liu, Y. circRNA_0016624 could sponge miR-98 to regulate BMP2 expression in postmenopausal osteoporosis. *Biochem. Biophys. Res. Commun.* **516**, 546–550 (2019).
31. Wen, J. et al. Circular RNA hsa_circ_0076906 competes with OGN for miR-1305 binding site to alleviate the progression of osteoporosis. *Int. J. Biochem. Cell Biol.* **122**, e105719 (2020).
32. Tang, X. et al. Review on circular RNAs and new insights into their roles in cancer. *Comput Struct. Biotechnol. J.* **19**, 910–928 (2021).